Megna Michael R
Megna Michael R, CAO, reported a transaction classified as exercise at Kiniksa Pharmaceuticals International, plc involving 3932.000000 shares for an estimated $0.00. Reported holdings after the transaction were 0.000000 shares. The stored filing text includes a detected 10b5-1 reference.
- Trade date
- Oct 30, 2026
- Filing date
- Nov 03, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
KNSA price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- exercise Code M
- Identifier
- 0001464583-26-000010 Share Option
- Transaction date
- Oct 30, 2026 Filed Nov 03, 2026, 11:26 PM · 4d delay
- Shares
- 3,932 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 0 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-20 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a meaningfully negative filing-only score. It is likely less useful as a positive insider-activity signal.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases. - tenb5_1_detected-10 points
is_10b5_1 = true
Stored filing content includes detected 10b5-1 language.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
CHIEF ACCOUNTING OFFICER
- F1
This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 30, 2026.
- F2
This transaction was executed in multiple trades through a broker-dealer at prices ranging between $91.275 and $92.26. The price reported in this column reflects a weighted average sales price. Upon r…
- F3
This transaction was executed in multiple trades through a broker-dealer at prices ranging between $92.28 and $93.27. The price reported in this column reflects a weighted average sales price. Upon re…
- F4
This transaction was executed in multiple trades through a broker-dealer at prices ranging between $93.42 and $94.38. The price reported in this column reflects a weighted average sales price. Upon re…
- F5
This transaction was executed in multiple trades through a broker-dealer at prices ranging between $94.42 and $95.22. The price reported in this column reflects a weighted average sales price. Upon re…
- F6
This transaction was executed in multiple trades through a broker-dealer at prices ranging between $95.485 and $96.405. The price reported in this column reflects a weighted average sales price. Upon…
- F7
This transaction was executed in multiple trades through a broker-dealer at prices ranging between $96.565 and $97.50. The price reported in this column reflects a weighted average sales price. Upon r…
- F8
This transaction was executed in multiple trades through a broker-dealer at prices ranging between $97.60 and $98.48. The price reported in this column reflects a weighted average sales price. Upon re…
- F9
The option is fully vested and exercisable.
- F10
The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting comme…
- F11
The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting comme…
0 other transactions
0 recent txs